Posted by Michael Wonder on 23 Feb 2018
Health Canada approves Bavencio (avelumab for injection) for the treatment of metastatic Merkel cell carcinoma in previously treated adult patients
22 February 2018 - First Health Canada approved treatment for rare and aggressive type of skin cancer.
EMD Serono Canada announced that Health Canada has approved Bavencio (avelumab for injection) for the treatment of metastatic Merkel cell carcinoma (MCC) in previously treated adults. Reviewed under Health Canada's accelerated approval framework, Bavencio was granted a Notice of Compliance with conditions based on tumour response and durability of response on 18 December 2017.
Bavencio, a fully human anti-PD-L1 antibody, is the first Health Canada approved treatment for patients with metastatic MCC, a rare and aggressive type of skin cancer.
